239
Participants
Start Date
October 31, 2009
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
Brincidofovir
Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
Placebo
"Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort."
Mt. Sinai School of Medicine, New York
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center Oncology, The Bronx
University of Rochester Medical Center, Rochester
Wake Forest University School of Medicine, Winston-Salem
UNC Health Care Center, Chapel Hill
Duke University Medical Center, Durham
Winship Cancer Institute at Emory University, Atlanta
The University of Alabama at Birmingham, Birmingham
The Cleveland Clinic, Cleveland
University of Michigan Medical School, Ann Arbor
Harper University Hospital, Detroit
University of Minnesota Medical Center, Minneapolis
University of Chicago Medical Center, Chicago
Baylor University Medical Center, Dallas
University of Texas, MD Anderson Cancer Center, Houston
University of Colorado Denver, Aurora
Utah Cancer Specialists - Intermountain Healthcare, Salt Lake City
UCLA Medical Center, Los Angeles
Moores UCSD Cancer Center, La Jolla
Oregon Health and Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
Brigham and Womens Hospital, Division of Infectious Disease, Boston
Nebraska Medical Center, Omaha
Hackensack University Medical Center, Hackensack
UT Southwestern Medical Center at Dallas, Dallas
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY